Healthcare Sales & Marketing Network News: XIENCE

Searching News Database: XIENCE

HSMN NewsFeed - 27 Oct 2021
HT Supreme(R) Drug Eluting Stent performs equivalent to best-in-class in the PIONEER III publication
Devices Interventional Cardiology

HSMN NewsFeed - 30 Jun 2021
Abbott's XIENCE Stent Receives FDA Approval for Shortest Blood Thinner Course for High Bleeding Risk Patients
Devices Interventional Cardiology FDA

HSMN NewsFeed - 23 May 2018
Newest Generation of Leading Heart Stent is Now Approved in the U.S. for People with Coronary Artery Disease
Devices Interventional Cardiology FDA

HSMN NewsFeed - 23 May 2018
mAbxience and Amneal Enter Into an Agreement for Bevacizumab Biosimilar in the United States
Biopharmaceuticals Generics Licensing

HSMN NewsFeed - 30 Oct 2017
Abbott Introduces Next Generation of Most Widely Used Heart Stent for People with Coronary Artery Disease in Europe[1]
Devices Interventional Cardiology Regulatory

HSMN NewsFeed - 28 Aug 2017
ESC Congress 2017: BIOTRONIK's Orsiro Drug-Eluting Stent Outperforms Xience in BIOFLOW-V Trial
Devices Interventional Cardiology

HSMN NewsFeed - 25 Jul 2017
Roxwood Medical Announces Agreement with Abbott for Distribution of Products in U.S.
Devices Interventional Cardiology Distribution

HSMN NewsFeed - 16 May 2017
Micell Technologies Announces MiStent Achieved Primary Endpoint in All-Comers Randomized Clinical Trial Versus Xience
Devices Interventional Cardiology

HSMN NewsFeed - 7 Nov 2016
Abbott's Absorb(TM) Bioresorbable Stent Approved as the First Fully Dissolving Heart Stent in Japan
Devices Interventional Cardiology Regulatory

HSMN NewsFeed - 16 Mar 2016
Abbott's Absorb(TM), the First Fully Dissolving Heart Stent, Earns Positive Review by FDA Advisory Committee
Devices Interventional Cardiology FDA

HSMN NewsFeed - 12 Oct 2015
Abbott Announces Positive Clinical Results of Absorb(TM), the Naturally Dissolving Heart Stent
Devices Interventional Cardiology

HSMN NewsFeed - 19 May 2015
Abbott Announces CE Mark for New Advancement of Absorb Stent System for People with Heart Disease
Devices Interventional Cardiology Regulatory

HSMN NewsFeed - 14 May 2015
EPIRUS Biopharmaceuticals and mAbxience Sign Latin America Distribution Deal for Infliximab Biosimilar, BOW015
Biopharmaceuticals Distribution

HSMN NewsFeed - 10 Jul 2013
Abbott Announces Approval of Next-Generation XIENCE Xpedition(TM) Drug Eluting Stent System in Japan
Devices Interventional Cardiology Regulatory

HSMN NewsFeed - 30 May 2013
Orsiro From BIOTRONIK, Industry's First Hybrid Drug-Eluting Stent, Performs as Best in Class
Devices Interventional Cardiology

HSMN NewsFeed - 21 May 2013
Abbott Announces CE Mark for World's Longest Coronary Drug Eluting Stent
Devices Interventional Cardiology Regulatory

HSMN NewsFeed - 8 Jan 2013
Abbott Initiates Clinical Trial of Absorb(TM) in the United States
Devices Interventional Cardiology

HSMN NewsFeed - 25 Sep 2012
Abbott Announces International Launch of the Absorb(TM) Bioresorbable Vascular Scaffold
Devices Interventional Cardiology

HSMN NewsFeed - 20 Aug 2012
Abbott Announces CE Mark and European Launch of Next-Generation XIENCE Xpedition� Drug Eluting Stent
Devices Interventional Cardiology Regulatory

HSMN NewsFeed - 30 May 2012
Kona Medical Secures $30M in Financing to Pursue Novel Hypertension Therapy
Devices Cardiology Venture Capital Personnel

HSMN NewsFeed - 18 May 2012
PROMUS Element(TM) Stent Demonstrates Excellent Long-Term Safety and Effectiveness in PLATINUM Small Vessel Study
Devices Interventional Cardiology

HSMN NewsFeed - 15 May 2012
Abbott's XIENCE PRIME(TM) and XIENCE V(R) Drug Eluting Stents Receive Indication in Europe for Minimum Three-Month Duration of Dual Anti-Platelet Therapy
Devices Interventional Cardiology Regulatory

HSMN NewsFeed - 9 Apr 2012
Abbott Receives Approval for Next-Generation XIENCE PRIME(TM) Drug Eluting Stent in Japan
Devices Interventional Cardiology Regulatory

HSMN NewsFeed - 22 Mar 2012
OrbusNeich's Genous(TM) Technology Effectively Promotes Endothelialization and Reduces Thrombogenicity
Devices Interventional Cardiology

HSMN NewsFeed - 8 Dec 2011
Abbott Initiates Clinical Trial to Evaluate the Absorb(TM) Bioresorbable Vascular Scaffold Compared to a Metallic Drug Eluting Stent
Devices Interventional Cardiology

HSMN NewsFeed - 4 Nov 2011
Medtronic�s Unmatched Portfolio of Cardiovascular Devices Features Prominently on Program for TCT 2011
Devices Interventional Cardiology

HSMN NewsFeed - 1 Nov 2011
Abbott Receives U.S. FDA Approval for Next-Generation XIENCE PRIME(TM) Drug Eluting Stent
Devices Interventional Cardiology FDA

HSMN NewsFeed - 8 Sep 2011
Abbott Initiates International ABSORB BTK Clinical Trial for Treatment of Below-the-Knee Critical Limb Ischemia
Devices

HSMN NewsFeed - 25 May 2011
Boston Scientific Announces FDA Approval and U.S. Launch of PROMUS(R) 2.25 mm Everolimus-Eluting Coronary Stent System
Devices Interventional Cardiology

HSMN NewsFeed - 18 May 2011
Industry�s First Hybrid Drug-Eluting Stent from BIOTRONIK Demonstrates Safety and Efficacy in First-in-Man Clinical Experience
Devices Interventional Cardiology

HSMN NewsFeed - 4 Apr 2011
Medtronic Resolute(R) Drug-Eluting Stent Delivers Compelling Clinical Outcomes in Major Studies
Devices Interventional Cardiology

HSMN NewsFeed - 28 Mar 2011
Medtronic to Unveil Pivotal U.S. Data on Resolute(R) Drug-Eluting Stent at ACC.11
Devices Interventional Cardiology

HSMN NewsFeed - 10 Jan 2011
Abbott Receives CE Mark Approval for World's First Drug Eluting Bioresorbable Vascular Scaffold for Treatment of Coronary Artery Disease
Devices Interventional Cardiology Regulatory

HSMN NewsFeed - 9 Dec 2010
Study Shows Novartis Drug Afinitor(R) Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 30 Sep 2010
CYPHER(R) Sirolimus Drug-Eluting Stent Remains Unsurpassed in Terms of Clinical Safety and Efficacy
Devices Interventional Cardiology

HSMN NewsFeed - 23 Sep 2010
Abbott's XIENCE V(R) Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial
Devices Interventional Cardiology

HSMN NewsFeed - 23 Sep 2010
Abbott's XIENCE V(R) Shows Outstanding Two-Year Clinical Results Versus TAXUS(R) in Key Safety and Efficacy Measures in SPIRIT IV Trial
Devices Interventional Cardiology

HSMN NewsFeed - 22 Sep 2010
Medtronic's Resolute Drug-Eluting Stent Shows Strong Performance in Second 'All Comers' Study
Devices Interventional Cardiology

HSMN NewsFeed - 26 May 2010
Boston Scientific Begins PLATINUM PLUS Trial for PROMUS(R) Element(TM) Stent System
Devices Interventional Cardiology

HSMN NewsFeed - 25 May 2010
Medtronic's Resolute(R) Drug-Eluting Stent Matches Market-Leading Rival in Large Head-to-Head Study
Devices Interventional Cardiology

HSMN NewsFeed - 20 May 2010
Boston Scientific Announces Schedule for EuroPCR 2010
Devices Interventional Cardiology

HSMN NewsFeed - 5 May 2010
The New England Journal of Medicine Publication of SPIRIT IV Trial Results Confirm Superior Safety and Efficacy of Abbott's XIENCE V(R) Drug Eluting Stent Compared to TAXUS
Devices Interventional Cardiology

HSMN NewsFeed - 8 Jan 2010
Boston Scientific Announces Japanese Approval for PROMUS(R) Everolimus-Eluting Coronary Stent System
Devices Interventional Cardiology Regulatory

HSMN NewsFeed - 2 Nov 2009
Boston Scientific Announces European Approval and Launch of Platinum Chromium PROMUS(R) Element(TM) Stent System
Devices Interventional Cardiology Regulatory

HSMN NewsFeed - 23 Sep 2009
Abbott's XIENCE V(R) Superior to TAXUS(R) in Key Safety and Efficacy Measures in SPIRIT IV Trial
Devices Interventional Cardiology

HSMN NewsFeed - 14 Sep 2009
Abbott Announces Approval in China for Next-Generation XIENCE V(R) Drug Eluting Stent
Devices Interventional Cardiology Regulatory

HSMN NewsFeed - 31 Aug 2009
Abbott Launches Next-Generation XIENCE PRIME(TM) Drug Eluting Stent in International Markets
Devices Interventional Cardiology

HSMN NewsFeed - 24 Aug 2009
Health Canada Approves Abbott's XIENCE V(R) Drug Eluting Stent
Devices Interventional Cardiology Regulatory

HSMN NewsFeed - 13 Aug 2009
Abbott Expands XIENCE V(R) USA Trial to Enroll Patients into Landmark Dual Anti-Platelet Therapy (DAPT) Trial
Devices Interventional Cardiology

HSMN NewsFeed - 23 Jun 2009
Abbott Receives CE Mark for Company's Next-Generation XIENCE PRIME(TM) Drug Eluting Stent, Advancing Leadership Position
Devices Interventional Cardiology Regulatory

HSMN NewsFeed - 16 Jun 2009
Abbott Initiates Trial of Next-Generation XIENCE PRIME(TM) Drug Eluting Stent, Building Upon Superior Outcomes from SPIRIT Family of Trials
Devices Interventional Cardiology

HSMN NewsFeed - 21 May 2009
Abbott's XIENCE V(R) Demonstrates Impressive Low Rates of Repeat Procedure, Stent Thrombosis and Major Adverse Cardiac Events in Complex, 'Real World' Patients in SPIRIT V Study
Devices Interventional Cardiology

HSMN NewsFeed - 19 May 2009
NEVO Sirolimus-Eluting Coronary Stent Yields Superior Results to Taxus Liberte Stent in Pivotal Clinical Trial
Devices Interventional Cardiology

HSMN NewsFeed - 19 May 2009
Boston Scientific Launches Third-Generation Platinum Chromium Drug-Eluting Stent
Devices Interventional Cardiology

HSMN NewsFeed - 15 May 2009
Boston Scientific Announces Schedule for EuroPCR 2009
Devices Interventional Cardiology

HSMN NewsFeed - 11 May 2009
Journal of American College of Cardiology Article Reports Fewer Repeat Procedures With Boston Scientific's TAXUS(R) Liberte(R) Stent
Devices Interventional Cardiology

HSMN NewsFeed - 9 Apr 2009
New Clinical Data at ACC09 Show the CYPHER Sirolimus-eluting Coronary Stent Outperformed TAXUS LIBERTE and ENDEAVOR Stents in Key Outcome Measures
Devices Interventional Cardiology

HSMN NewsFeed - 1 Apr 2009
Abbott Initiates U.S. Study of Absolute Pro(TM) Peripheral Stent System for Iliac Artery Disease
Devices Interventional

HSMN NewsFeed - 26 Mar 2009
Boston Scientific Announces Schedule For ACC 2009
Devices Interventional Cardiology

HSMN NewsFeed - 24 Mar 2009
Abbott Advances Its Revolutionary Fully Bioabsorbable Drug Eluting Stent With Initiation of Next Phase of Clinical Trial
Devices Interventional Cardiology

HSMN NewsFeed - 16 Mar 2009
Cordis Corporation Announces Head-to-Head Randomized Clinical Trial Comparing the NEVO Sirolimus-Eluting Coronary Stent to the XIENCE Stent
Devices Interventional Cardiology

HSMN NewsFeed - 12 Mar 2009
The Lancet Publishes Two-Year Results of Abbott's Fully Bioabsorbable Drug Eluting Stent
Devices Interventional Cardiology

HSMN NewsFeed - 10 Mar 2009
Abbott Launches VOYAGER(TM) NC Coronary Balloon Catheter
Devices Interventional Cardiology

HSMN NewsFeed - 5 Feb 2009
Boston Scientific Submits Final Modules to FDA for Approval of Second-Generation Small Vessel and Long Lesion Stents
Devices Interventional Cardiology

HSMN NewsFeed - 26 Jan 2009
Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
Devices Interventional Cardiology

HSMN NewsFeed - 20 Jan 2009
Abbott Opens New Pharmaceutical Research Laboratory in Singapore
Biopharmaceuticals

HSMN NewsFeed - 17 Dec 2008
Abbott Begins U.S. Study of XIENCE V(TM) Drug Eluting Stent Designed for Small Vessels
Devices Interventional Cardiology

HSMN NewsFeed - 13 Oct 2008
Abbott's XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
Devices Interventional Cardiology

HSMN NewsFeed - 10 Oct 2008
Boston Scientific Announces FDA Approval of Second-Generation TAXUS(R) Liberte(R) Drug-Eluting Stent
Devices Interventional Cardiology FDA

HSMN NewsFeed - 15 Sep 2008
Medtronic Starts U.S. and International Trials of Endeavor(R) Resolute Drug-Eluting Coronary Stent
Devices Interventional Cardiology

HSMN NewsFeed - 3 Jul 2008
FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent
Devices Interventional Cardiology FDA

HSMN NewsFeed - 2 Jun 2008
Abbott Submits Application for Approval of XIENCE(TM) V Everolimus Eluting Coronary Stent System in Japan
Devices Interventional Cardiology Regulatory

HSMN NewsFeed - 14 May 2008
XIENCE(TM) V Drug Eluting Stent from Abbott Reduces Major Adverse Cardiac Events in Small Vessel Patients Out to One Year
Devices Interventional Cardiology

HSMN NewsFeed - 13 May 2008
SPIRIT III Results Reaffirm Strong Performance of Boston Scientific PROMUS(TM) and TAXUS(R) Express(R) Stents
Devices Interventional Cardiology

HSMN NewsFeed - 13 May 2008
XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
Devices Interventional Cardiology

HSMN NewsFeed - 12 May 2008
Medtronic Announces Start of International Study Comparing Endeavor(R) Resolute Drug-Eluting Stent to Abbott's Xience(R) V
Devices Interventional Cardiology

HSMN NewsFeed - 22 Apr 2008
Study in JAMA Shows Patients Treated With Abbott's XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
Devices Interventional Cardiology

HSMN NewsFeed - 31 Mar 2008
Spirit II Results Support Strength of Boston Scientific's Two Drug-Eluting Stent Platforms
Devices Interventional Cardiology

HSMN NewsFeed - 31 Mar 2008
SPIRIT II Explores Long-Term Performance of XIENCE V Stent
Devices Interventional Cardiology

HSMN NewsFeed - 31 Mar 2008
Abbott's XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
Devices Interventional Cardiology

HSMN NewsFeed - 11 Mar 2008
Abbott Receives CE Mark for Smaller-Size XIENCE(TM) V Drug Eluting Stent
Devices Interventional Cardiology Regulatory

HSMN NewsFeed - 11 Feb 2008
Boston Scientific Announces Start of Major European Registry Assessing Different Olimus-Eluting Stents
Devices Interventional Cardiology

HSMN NewsFeed - 4 Feb 2008
Tryton Medical Receives CE Mark Approval for its Side-Branch Stent
Devices Regulatory Interventional Cardiology

HSMN NewsFeed - 1 Feb 2008
Abbott Gains Reimbursement for XIENCE(TM) V Drug Eluting Stent in France
Devices Reimbursement Interventional Cardiology

HSMN NewsFeed - 29 Nov 2007
Boston Scientific Welcomes FDA Panel Recommendation to Approve PROMUS(TM) / XIENCE(TM) V Everolimus-eluting Coronary Stent System
Devices Interventional Cardiology

HSMN NewsFeed - 29 Nov 2007
FDA Advisory Committee Recommends Approval of Abbott's XIENCE(TM) V Drug Eluting Stent System
Devices Interventional Cardiology

HSMN NewsFeed - 27 Nov 2007
Abbott to Present Comprehensive Safety and Efficacy Data on XIENCE(TM) V Drug Eluting Stent to FDA Advisory Committee on Nov. 29
Devices Interventional Cardiology

HSMN NewsFeed - 5 Nov 2007
Abbott Confirms FDA Advisory Panel to Review XIENCE(TM) V Drug Eluting Stent on November 29
Devices Interventional Cardiology FDA

HSMN NewsFeed - 22 Oct 2007
Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
Devices Interventional Cardiology

HSMN NewsFeed - 22 Oct 2007
Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
Devices Interventional Cardiology

HSMN NewsFeed - 19 Jul 2007
Abbott Enrolls First Patient in World's First Clinical Trial Designed to Study Drug Eluting Stent Treatment in Women
Devices Interventional Cardiology

HSMN NewsFeed - 1 Jun 2007
Abbott Submits XIENCE(TM) V Everolimus Eluting Coronary Stent System Application for U.S. FDA Approval
Devices Interventional Cardiology

HSMN NewsFeed - 23 May 2007
Abbott Initiates First Clinical Study of Everolimus Eluting Stent System for Patients with Peripheral Arterial Disease
Devices Interventional

HSMN NewsFeed - 22 May 2007
SPIRIT Clinical Data Reaffirm Strength of TAXUS(R) and PROMUS(TM) Drug-Eluting Coronary Stent Systems
Devices Interventional Cardiology

HSMN NewsFeed - 22 May 2007
Abbott Announces Continued Positive Results with XIENCE(TM) V Everolimus Eluting Coronary Stent in SPIRIT Clinical Trials
Devices Interventional Cardiology

HSMN NewsFeed - 15 May 2007
Boston Scientific Announces Schedule for EuroPcr 2007
Devices Interventional Cardiology

HSMN NewsFeed - 26 Apr 2007
Northstar Neuroscience Announces Management and Board Succession Plan
Devices Neurology Personnel

HSMN NewsFeed - 16 Apr 2007
COURAGE, SPIRIT Data May Support Role of Advanced Imaging and Diagnosis With IVUS and FFR
Devices Interventional Cardiology

HSMN NewsFeed - 24 Mar 2007
Spirit III Clinical Trial Demonstrates Positive Performance for Both TAXUS(R) and PROMUS(TM) Drug-Eluting Stent Systems
Devices Interventional Cardiology

HSMN NewsFeed - 24 Mar 2007
Abbott's XIENCE(TM) V Everolimus Eluting Coronary Stent Superior to TAXUS(R) Stent in SPIRIT III U.S. Pivotal Clinical Trial
Devices Interventional Cardiology

HSMN NewsFeed - 20 Mar 2007
Boston Scientific Announces Schedule for ACC 2007
Devices Interventional Cardiology

HSMN NewsFeed - 6 Feb 2007
Abbott to Initiate First Study to Evaluate XIENCE(TM) V Everolimus Eluting Coronary Stent System in Treatment of Women With Cardiovascular Disease
Devices Interventional Cardiology

HSMN NewsFeed - 11 Jan 2007
Private-Label Version of Abbott's XIENCE(TM)V Drug-Eluting Coronary Stent System Launches in Europe
Devices Interventional Cardiology

HSMN NewsFeed - 11 Jan 2007
Boston Scientific Announces First Use of PROMUS(TM) Everolimus-Eluting Stent System
Devices Interventional Cardiology

HSMN NewsFeed - 4 Jan 2007
French Court Rules in Favor of evYsio Medical Devices in Patent Litigation Against Abbott Laboratories
Devices Interventional Cardiology Litigation

HSMN NewsFeed - 28 Nov 2006
Northstar Neuroscience Announces Management Additions; Names Chief Operating Officer and Hires Vice President of Regulatory Affairs and Quality Assurance
Devices Neurology Personnel

HSMN NewsFeed - 25 Oct 2006
Safety and Efficacy Benefits of Next-Generation TAXUS(R) Liberte(TM) Stent Sustained at Twelve Months
Devices Interventional Cardiology

HSMN NewsFeed - 25 Oct 2006
Data in Complex Patients and Lesions from OLYMPIA Registry Support Safety and Efficacy of TAXUS(R) Liberte(TM) Stent System
Devices Interventional Cardiology

HSMN NewsFeed - 24 Oct 2006
Abbott Reports Initial Results From World's First Clinical Trial Featuring a Fully Bioabsorbable Drug-Eluting Coronary Stent
Devices Interventional Cardiology

HSMN NewsFeed - 18 Oct 2006
Boston Scientific to Highlight Broad Range of Clinical Trial Results Reinforcing Safety and Efficacy of TAXUS(R) Coronary Stent Systems at TCT 2006
Devices Interventional Cardiology

HSMN NewsFeed - 17 Oct 2006
Abbott to Present New Data Across Its Vascular Portfolio at TCT 2006
Devices Interventional Cardiology

HSMN NewsFeed - 16 Oct 2006
Boston Scientific Becomes only Company with Two Drug-Eluting Stent Platforms With European Approval of Everolimus-Eluting PROMUS(TM) Stent System
Devices Interventional Cardiology Regulatory

HSMN NewsFeed - 3 Oct 2006
Abbott Begins Early International Launch of XIENCE(TM) V Everolimus Eluting Coronary Stent System
Devices Interventional Cardiology

HSMN NewsFeed - 12 Sep 2006
Abbott Announces Continued Expansion of Vascular Operations in Ireland to Prepare for Drug Eluting Stent Manufacturing
Devices Interventional Cardiology

HSMN NewsFeed - 5 Sep 2006
SPIRIT II Results Highlight Strength of Boston Scientific Stent Portfolio
Devices Interventional Cardiology

HSMN NewsFeed - 5 Sep 2006
Abbott's XIENCE V(TM) Drug-Eluting Coronary Stent Superior to TAXUS(R) Stent in SPIRIT II Clinical Trial
Devices Interventional Cardiology

HSMN NewsFeed - 1 Sep 2006
PROMUS(TM) Everolimus-Eluting Stent Added to Boston Scientific Coronary Stent Portfolio
Devices Interventional Cardiology

HSMN NewsFeed - 14 Aug 2006
Abbott Enrolls First Patient in New Clinical Trial of XIENCE(TM) V Drug Eluting Stent
Devices Interventional Cardiology

HSMN NewsFeed - 21 Apr 2006
Abbott Completes Acquisition of Guidant Vascular Business
Devices Cardiology Mergers & Acquisitions

HSMN NewsFeed - 29 Mar 2006
Guidant to Temporarily Suspend XIENCE V Supply
Devices Interventional Cardiology

HSMN NewsFeed - 28 Mar 2006
Medtronic Sues Guidant in Ireland
Devices Interventional Cardiology Litigation

HSMN NewsFeed - 30 Jan 2006
Guidant Receives European Approval for Drug Eluting Coronary Stent
Devices Interventional Cardiology Regulatory

HSMN NewsFeed - 24 Jan 2006
Guidant Receives Recommendation for Approval from European Competent Authority for Drug Eluting Stent
Devices Interventional Cardiology Regulatory

Return to NewsFeed

Additional items found! 7

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 7 additional stories matching:
XIENCE
(Password required)

FindReps - available on the Apple App Store for iPhone and iPad.